The shipment was sent to ITM Isotope Technologies in Munich, where the isotopes were then processed into doses of no-carrier-added Lu-177 and distributed to healthcare facilities around the world. Lu-177 is used in several clinical and commercial cancer treatments.

With production capabilities achieved, officials said commissioning activities can now be completed this summer, followed by commercial operations, pending final regulatory review and approval by the Canadian Nuclear Safety Commission.